Skip to main content
SpringerLink
Log in

Types of Circulating Tumor Markers and Their Clinical Applications

  • Chapter
Cancer Diagnostics

Part of the book series: Contemporary Cancer Research ((CCR))

  • 147 Accesses

Abstract

It was during the 1950s and 1960s when we began to realize that the concentration of many molecules circulating in the blood reflected tumor cell activity. Because blood could be sampled repeatedly, these circulating molecules were used to monitor the success of cancer treatment in patients, which allowed for the adjustment of therapeutic regiment from time to time. These molecules included enzymes, isoenzymes, serum proteins, and hormones that could be found in normal blood circulation (1).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bodansky O. 1974. Reflections on biochemical aspects of human cancer. Cancer 33:364–371.

    Article  PubMed  CAS  Google Scholar 

  2. Warburg O. 1956. On the origin of cancer cells. Science 123:309–314.

    Article  PubMed  CAS  Google Scholar 

  3. Coombes RC, Powles TJ, Gazet JC, et al. 1977. Biochemical markers in human breast cancer. Lancet 1:132Y–137.

    Article  Google Scholar 

  4. Yuce K, Baykal C, Gene C, Al A, Ayhan A. 2001. Diagnostic and prognostic value of serum and peritoneal fluid lactate dehydrogenase in epithelial ovarian cancer. Eur. J. Gynaecol. Oncol. 22:228–232.

    PubMed  CAS  Google Scholar 

  5. Fishman WH, Inglis NI, Stolbach LL, et al. 1968. A serum alkaline phosphatase isoenzyme of human neoplastic cell origin. Cancer Res. 28:150–154.

    PubMed  CAS  Google Scholar 

  6. Gold P and Freedman SO. 1963. Demonstration of tumour specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques. J. Exptl. Med. 121:439–61.

    Article  Google Scholar 

  7. Thomson DMP, Krupey J, Freedman SO, et al. 1969. The radioimmunoaasy of circulating carcinoembryonic antigen of the human digestive system. Proc. Natl. Acad. Sci. USA 64:161–167.

    Article  PubMed  CAS  Google Scholar 

  8. Takasaki H, Uchida E, Tempero MA, et al. 1988. Correlative study on expression of CA 19–9 and DU-PAN-2 in tumor tissue and in serum of pancreatic cancer patients. Cancer Res. 48: 1435–1438.

    PubMed  CAS  Google Scholar 

  9. Fukuta S, Magnani JL, Gaur PK, et al. 1987. Monoclonal antibody CC3C 195, which detects cancer-associated antigens in serum, binds to human Lea blood group antigen and to its sialylated derivative. Arch. Biochem. Biophys. 255:214–2146.

    Article  PubMed  CAS  Google Scholar 

  10. Blaszczyk M, Pak KY, Herlyn M, et al. 1985. Characterization of Lewis antigens in normal colon and gastrointestinal adenocarcinomas. Proc. Natl. Acad. Sci. USA 82:3552–3556.

    Article  PubMed  CAS  Google Scholar 

  11. Stroud MR, Levery SB, Nudelman ED, et al. 1991. Extended type 1 chain glycosphingolipids: dimeric Lea(III4V4Fuc2Lc6) as human tumor-associated antigen. J. Biol. Chem. 266:8439–8446.

    PubMed  CAS  Google Scholar 

  12. Dimmons DA and Rand Perlmann P. 1973. Carcinoembryonic antigen and blood group substances. Cancer Res. 33:313–322.

    Google Scholar 

  13. Holburn AM, Mach JP, Mac Donald D, et al. 1974. Studies of the association of the A, B, and Lewis blood group antigens with carcinoembryonic antigen (CEA). Immunology 26:831–843.

    PubMed  CAS  Google Scholar 

  14. Ball JP, Magous R, Lecou C, et al. 1976. Presence of blood group H antigen on a carcinoembryonic antien, and its enzymatic modification into blood group A and B specificities. Cancer Res. 36:2124–2129.

    Google Scholar 

  15. Magnani JL, Steplewski Z, Koprowski H, et al. 1983. Identification of the gastrointestinal and pancreatic cancer-associated antigen detected by monoclonal antibody 19–9 in the sera of patients as a mucin. Cancer Res. 43:5489–5492.

    PubMed  CAS  Google Scholar 

  16. Feizi T, Turberville C, Westwood JH. 1975. Blood-group precursors and cancer-related antigens. Lancet 2:391–393.

    Article  PubMed  CAS  Google Scholar 

  17. Dabelsteen E, Graem N, Clausen H, et al. 1988. Structural variations of blood group A antigens in human normal colon and carcinomas. Cancer Res. 48:181–187.

    PubMed  CAS  Google Scholar 

  18. Narita T, Funahashi, Satoh Y, et al. 1993. Association of expression of blood group-related carbohydrate antigens with prognosis in breast cancer. Cancer 71:3044–3053.

    Article  PubMed  CAS  Google Scholar 

  19. Hughes JH and Cohen MB. 1999. Nuclear matrix proteins and their potential applications to diagnostic pathology. Am. J. Clin. Pathol. 111:267–274.

    PubMed  CAS  Google Scholar 

  20. Davis F, Gyorkey F, Busch RK, Busch H. 1979. Nucleolar antigen found in several human tumors but not in the nontumor tisses studied. Proc. Natl. Acad. Sci. USA 76:892–896.

    Article  PubMed  CAS  Google Scholar 

  21. Ishii T, Okadome A, Takeuchi F, Hiratsuka Y. 2001. Urinary levels of nuclear matrix protein 22 in patients with urinary diversion. Urology 58:940–942.

    Article  PubMed  CAS  Google Scholar 

  22. Konety BR, Nguyen TS, Dhir R, et al. 2000. Detection of bladder cancer using a novel nuclear matrix protein, BLCA-4. Clin. Cancer Res. 6:2618–2625.

    PubMed  CAS  Google Scholar 

  23. Keesee SK, Meyer JL, Hutchinson ML, et al. 1999. Preclinical feasibility study of NMP179, a nuclear matrix protein marker for cervical dysplasia. Acta. Cytol. 43:1015–1022.

    Article  PubMed  CAS  Google Scholar 

  24. Collazos J and Rodriguez J. 1993. Squamous cell carcinoma antigen in patients with cirrhosis. Clin. Chem. 39:548–553.

    PubMed  CAS  Google Scholar 

  25. Molina R, Filelia Z, Torres MD, et al. 1990. SCC antigen measured in maliganat and nonmalig-nant diseases. Clin. Chem. 36:251–254.

    PubMed  CAS  Google Scholar 

  26. Sarandakou A, Phocas I, Botsis D, et al. 1998. Tumour-associated antigens CEA, CA125, SCC and TPS in gynaecological cancer. Eur. J. Gynaecol. Oncol. 19:73–77.

    PubMed  CAS  Google Scholar 

  27. Wu T-L, Chang CP-Y, Tsao K-C, Sun C-F, Wu JT. 1999. Development of a microplate assay for serum chromogranin A (CgA): establishment of normal reference values and the detection of elevated CgA in carcinomas. J. Clin. Lab. Anal. 13:312–319.

    Article  PubMed  CAS  Google Scholar 

  28. Tsao KC and Wu JT. 2001. Development of an ELISA for the detection of serum chromogranin A (CgA) in prostate and non-neuroendocrine carcinomas Clin. Chim. Acta. 313:21–29.

    Article  CAS  Google Scholar 

  29. Burghuber OC, Worofka B, Schernthaner G, et al. 1990. Serum neuron-specific enolase is a useful tumor marker for small cell lung cancer. Cancer 65:1386–1390.

    Article  PubMed  CAS  Google Scholar 

  30. Collazos J and Rodriguez J. 1993. Squamous cell carcinoma antigen in patients with cirrhosis. Clin. Chem. 39:548–553.

    PubMed  CAS  Google Scholar 

  31. Graeff H, Harbeck N, Pache L, et al. 1992. Prognostic impact and clinical relevance of tumor-associated proteases in breast cancer. Fibrinolysis 6(Suppl 4):45–53.

    Google Scholar 

  32. Fidler IJ and Hart IR. 1982. Biological diversity in metastatic neoplasms:origins and implications. Science 217:998–1003.

    Article  PubMed  CAS  Google Scholar 

  33. Miyamoto KK, Mcsherry SA, Robins SP, et al. 1994. Collagen cross-link metabolites in urine as markers of bone metastases in prostatic carcinoma. J. Urol. 151:909–913.

    PubMed  CAS  Google Scholar 

  34. Collier IE, Wilhelm SM, Eisen AZ, et al. 1988. H-ras oncogene-transformed human bronchial epithelial cells (TBE-1) secrete a single metalloprotease capable of degrading basement membrane collagen. J. Biol. Chem. 263:6579–6587.

    PubMed  CAS  Google Scholar 

  35. Graeff H, Harbeck N, Pache L, et al. 1992. Prognostic impact and clinical relevance of tumor-associated proteases in breast.

    Google Scholar 

  36. Wolf C, Rouyer N, Lutz Y, et al. 1993. Stromelysin 3 belongs to a subgroup of proteinases expressed in breast carcinoma fibroblastic cells and possibly implicated in tumor progression. Proc. Natl. Acad. Sci. USA 90:1843–1847.

    Article  Google Scholar 

  37. D’Alessandro R, Roselli M, Ferroni P, et al. 2001. Serum tissue polypeptide specific antigen (TPS): a complementary tumor marker to CA 15–3 in the management of breast cancer. Breast Cancer Res. Treat. 68:9–19.

    Article  PubMed  Google Scholar 

  38. Sjostrom J, Alfthan H, Joensuu H, Stenman UH, Lundin J, Blomqvist C. 2001. Serum tumour markers CA 15–3, TPA, TPS, hCGbeta and TATI in the monitoring of chemotherapy response in metastatic breast cancer. Scand. J. Clin. Lab. Invest. 61:431–441.

    Article  PubMed  CAS  Google Scholar 

  39. Perret AG, Mosnier JF, Buono JP, et al. 1998. The relationship between MIB-1 proliferation index and outcome in pancreatic neuroendocrine tumors. Am. J. Clin. Pathol. 109:286–293.

    CAS  Google Scholar 

  40. Ogala K, Kurki P, Celis JE, et al. 1987. Monoclonal antibodies to nuclear protein (PCNA/clclin) associated with DNA replication. Exp. Cell. Res. 168:475–486.

    Article  Google Scholar 

  41. 26.

    Google Scholar 

  42. Rastel D, Ramaioli A, Cornillie F, Thirion B. 1994. CYFRA 21–1, a sensitive and specific new tumour marker for squamous cell lung cancer. Report of the first European multicentre evaluation. European J. Cancer 30A:601–606.

    Article  CAS  Google Scholar 

  43. Kulpa J, Wojcik E, Radkowski A, Kolodziejski L, Stasik Z. 2000. CYFRA 21–1, TPA-M, TPS, SCC-Ag and CEA in patients with squamous cell lung cancer and in chemical industry workers as a reference group. Anticancer Res. 20:5035–5040.

    Google Scholar 

  44. Sanchez-Carbayo M, Herrero E, Megias J, Mira A, Soria F. 1999. Comparative sensitivity of urinary CYFRA 21–1, urinary bladder cancer antigen, tissue polypeptide antigen, tissue polypeptide antigen. J. Urol. 6:1951–1956.

    Article  Google Scholar 

  45. Wang N, He Q, Skog S, Eriksson S, Tribukait B. 2001 Investigation on cell proliferation with a new antibody against thymidine kinasel. Anal. Cell. Pathol. 23:11–19.

    PubMed  Google Scholar 

  46. Clark GM, Alfred DC, Hilsenbeck SG, et al. 1997. Mitosin (a new proliferation marker) correlates with clinical outcome in node-negative breast cancer. Cancer Res. 57:5505–5508.

    PubMed  CAS  Google Scholar 

  47. Yogeeswaran G and Salk PL. 1981. Metastatic potential is positively correlated. Science 212:1514–1516.

    Article  PubMed  CAS  Google Scholar 

  48. Dnistrian AM, Smith C, and Schwartz MK. 1986. Sialic acid as a tumor marker. Clin. Invest. 27:156–159.

    Google Scholar 

  49. Dwivedi C, Dixit M, Hardy REK. 1990. Plasma lipid-bound sialic acid alterations in neoplastic diseases. Acta. Diabetol. Lat. 27:357–364.

    Article  Google Scholar 

  50. Petru E, Sevin BU, Averette HE, et al. 1990. Comparison of three tumor markers-CA-125, lipd-associated sialic acid (LSA), and NB/70k-in monitoring ovarian cancer. Gynecol. Oncol. 38: 181–186.

    Article  PubMed  CAS  Google Scholar 

  51. Brown J A and Roberts CS. 1992. Elevated serum a-fetoprotein levels in primary gallbladder carcinoma without hepatic involvement. Cancer 70:1838–1840.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. James T. Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Scripps Clinic, La Jolla, CA, USA

    Robert M. Nakamura MD

  2. UCLA School of Medicine, Los Angeles, CA, USA

    Wayne W. Grody MD, PhD

  3. ARUP Labs, Salt Lake City, UT, USA

    James T. Wu PhD

  4. Arizona Cancer Center, Tucson, AZ, USA

    Raymond B. Nagle MD, PhD

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Springer Science+Business Media New York

About this chapter

Cite this chapter

Wu, J.T. (2004). Types of Circulating Tumor Markers and Their Clinical Applications. In: Nakamura, R.M., Grody, W.W., Wu, J.T., Nagle, R.B. (eds) Cancer Diagnostics. Contemporary Cancer Research. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-791-8_4

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-791-8_4

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-61737-399-2

  • Online ISBN: 978-1-59259-791-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation